Investments on behalf of former President Donald Trump in pharmaceutical companies have risen sharply since he resumed office last year, according to a report from congressional Democrats. The report indicates that Trump’s stock holdings in these firms grew significantly following a Republican-backed law that exempts certain medications from Medicare price negotiations.
Released by the minority arm of the Joint Economic Committee, the report outlines that Trump’s pharmaceutical investments escalated from a maximum estimated value of $1.7 million in 2024 to nearly $56.2 million by the close of 2025. This includes up to $39.1 million in stock linked to companies that received exemptions from Medicare’s drug price negotiation program as part of the 2025 tax and spending law supported by Republicans.
Further analysis of Trump’s financial disclosures disclosed that his portfolio purchased as much as $2.55 million in shares of pharmaceutical companies favored by the exemptions three times before he signed the legislation into law in July 2025. This included investments amounting to approximately $950,000 on July 1, 2025, coinciding with the Senate’s passage of the bill. Additionally, Trump’s portfolio acquired up to $1 million in shares of AbbVie in August 2025 following the bill’s enactment.
The increase in Trump’s wealth has drawn scrutiny, as many of his investments appear to align with policy decisions made during his presidency. The White House has dismissed concerns about potential ethical conflicts, suggesting that Democrats are attempting to fabricate issues regarding Trump’s financial interests.
Democratic Senator Maggie Hassan, chair of the Joint Economic Committee’s minority arm, criticized the findings as “outrageous yet typical” behavior from Trump, asserting that he continues to benefit at the expense of Americans. Meanwhile, White House spokesperson Davis Ingle emphasized that Trump’s financial portfolio is managed by independent entities, asserting that neither Trump nor his family can influence investment decisions.
A recent law under President Joe Biden allows Medicare to negotiate prices for some high-cost prescription drugs for the first time. In contrast, the Republican 2025 tax bill broadened existing exemptions for medications intended for rare diseases, delaying or preventing negotiations on some high-priced drugs. Critics argue that these policies restrict efforts to lower drug costs for Medicare beneficiaries. The report estimates that Medicare recipients using cancer medications like Keytruda and Opdivo could face annual costs up to $5,000 higher than if negotiations were permitted.
Throughout the first eight months of 2026, Trump’s portfolio reportedly continued to buy and sell pharmaceutical stocks, adding as much as $3.5 million in wealth from this sector. In a departure from norms set by prior presidents, Trump did not divest from his stocks upon assuming office. His investments are held in a trust managed by his sons, which lacks the conflict of interest protections established by his predecessors.
